Search
Research
The seroprevalence of SARS-CoV-2-specific antibodies in children, Australia, November 2020 - March 2021Peter Britta Richmond Regli-von Ungern-Sternberg AM FAHMS MBBS MRCP(UK) FRACP MD, PhD, DEAA, FANZA Head, Vaccine Trials Group Chair of Paediatric
Research
Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative ReviewThe search for clinically effective antivirals against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is ongoing. Repurposing of drugs licensed for non–coronavirus disease 2019 (COVID-19) indications has been extensively investigated in laboratory models and in clinical studies with mixed results.
Research
Calling Future Grandparents-Further Efforts Required to Increase Human Papillomavirus Vaccination Use in AdolescenceChristopher Blyth MBBS (Hons) DCH FRACP FRCPA PhD Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases
Research
The prevalence of tuberculosis and malaria in minority indigenous populations of South- East Asia and the Western Pacific Region: a systematic review and meta-analysisInfectious diseases have been shown to disproportionately affect indigenous populations. Tuberculosis (TB) and malaria continue to impose a significant burden on humanity and are among the infectious diseases targeted within the 2030 Agenda for Sustainable Development.
Research
Inequalities in excess premature mortality in England during the COVID-19 pandemic: A cross-sectional analysis of cumulative excess mortality by area deprivation and ethnicityTo examine magnitude of the impact of the COVID-19 pandemic on inequalities in premature mortality in England by deprivation and ethnicity.
Research
Developing a prediction model to estimate the true burden of respiratory syncytial virus (RSV) in hospitalised children in Western AustraliaRespiratory syncytial virus (RSV) is a leading cause of childhood morbidity, however there is no systematic testing in children hospitalised with respiratory symptoms. Therefore, current RSV incidence likely underestimates the true burden.
Research
Risk factors associated with unsuccessful tuberculosis treatment outcomes in Hunan Province, ChinaGlobally, China has the third highest number of tuberculosis (TB) cases despite high rates (85.6%) of effective treatment coverage. Identifying risk factors associated with unsuccessful treatment outcomes is an important component of maximising the efficacy of TB control programmes.
Research
Persistence of the immune responses and cross-neutralizing activity with Variants of Concern following two doses of adjuvanted SCB-2019 COVID-19 vaccineWe have previously reported the safety and immunogenicity four weeks after two doses of the Clover COVID-19 vaccine candidate, SCB-2019, a stabilized pre-fusion form of the SARS-CoV-2 S-protein (S-trimer). We now report persistence of antibodies up to 6 months after vaccination, and cross-neutralization titers against three Variants of Concern.
Research
Prospective characterisation of SARS-CoV-2 infections among children presenting to tertiary paediatric hospitals across Australia in 2020: A national cohort studyTo present Australia-wide data on paediatric COVID-19 and multisystem inflammatory syndromes to inform health service provision and vaccination prioritisation. Design Prospective, multicentre cohort study. Setting Eight tertiary paediatric hospitals across six Australian states and territories in an established research surveillance network - Paediatric Active Enhanced Disease (PAEDS).
Research
Excess respiratory mortality and hospitalizations associated with influenza in Australia, 2007-2015Influenza is the most common vaccine-preventable disease in Australia, causing significant morbidity and mortality. We assessed the burden of influenza across all ages in terms of influenza-associated mortality and hospitalizations using national mortality, hospital-discharge and influenza surveillance data.